Bristol Myers Squibb Competitors and Similar CompaniesClear all
Daiichi Sankyo's competitors and similar companies include Regeneron Pharmaceuticals, Gilead Sciences, Edwards Lifesciences, Lonza, Catalent, Pfizer, Johnson & Johnson, AbbVie, Merck Group, AstraZeneca and Lilly.
 Daiichi Sankyo Daiichi Sankyo (第一三共株式会社) is a company specializing in the research, development, and manufacture of innovative pharmaceutical products. |  Regeneron Pharmaceuticals Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines. |  Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines. |  Edwards Lifesciences Edwards Lifesciences is a provider of patient-focused medical solutions for structural heart disease and critical care monitoring. |  Catalent Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. |  Johnson & Johnson Johnson & Johnson (J&J) is a company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field. |  AbbVie AbbVie is a pharmaceutical company engaged in the research, development, manufacturing, commercialization, and sale of medicines and therapies. |  AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. |  Lilly Eli Lilly is a company that discovers, develops, manufactures, and markets pharmaceutical products. | |||
Founding Date | Founding Date 2005 | Founding Date 1988 | Founding Date 1987 | Founding Date 1958 | Founding Date 1897 | Founding Date 2007 | Founding Date 1849 | Founding Date 1886 | Founding Date 2013 | Founding Date 1668 | Founding Date 1999 | Founding Date 1876 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||||||
Locations | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Braine L'alleud, BE Sao Paulo, BR Toronto, CA Shanghai, CN see more | Locations Tarrytown, US HQ Mississauga, CA Courbevoie, FR München, DE Bengaluru, IN Dublin, IE Limerick, IE see more | Locations Foster City, US HQ Buenos Aires, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more | Locations Irvine, US HQ Macquarie Park, AU Wien, AT Dilbeek, BE São Paulo, BR Mississauga, CA Shanghai, CN see more | Locations Basel, CH HQ Baulkham Hills, AU Antwerpen, BE Bornem, BE Verviers, BE Rio De Janeiro, BR Dorval, CA see more | Locations Bridgewater, US HQ Buenos Aires, AR Bruxelles, BE Charleroi, BE Charleroi, BE Charleroi, BE Indaiatuba, BR see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more | Locations New Brunswick, US HQ Buenos Aires, AR Sydney, AU Vienna, AT Minsk, BY Beerse, BE Sofia, BG see more | Locations North Chicago, US HQ Hydra, DZ Buenos Aires, AR Mascot, AU Wien, AT Wavre, BE Sarajevo, BA see more | Locations Darmstadt, DE HQ Buenos Aires, AR Bayswater, AU Macquarie Park, AU Wien, AT Hoeilaart, BE Rio De Janeiro, BR see more | Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU Wien, AT see more | Locations Indianapolis, US HQ Buenos Aires, AR Sydney, AU Wien, AT Brussel, BE São Paulo, BR Toronto, CA see more |
Employees | Employees 18,726 | Employees 15,1068% increase | Employees 18,0006% increase | Employees 15,80020% decrease | Employees 19,7712% increase | Employees 12,6955% increase | Employees 81,0008% decrease | Employees 138,1005% increase | Employees 55,00010% increase | Employees 62,34615% decrease | Employees 94,300 | Employees 47,0009% increase |
Valuation ($) | Valuation ($) 61.7 b | Valuation ($) 102.2 b | Valuation ($) 110.5 b | Valuation ($) 41.8 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 163.9 b | Valuation ($) 396.3 b | Valuation ($) 335 b | Valuation ($) 71.6 b | Valuation ($) 2.7 b | Valuation ($) 903.4 b |
Financial | ||||||||||||
Revenue (est.) | Revenue (est.) ¥1.9t (FY, 2024) | Revenue (est.) $14.3b (FY, 2025) | Revenue (est.) $29.4b (FY, 2025) | Revenue (est.) $6.1b (FY, 2025) | Revenue (est.) CHF6.5b (FY, 2025) | Revenue (est.) $4.4b (FY, 2024) | Revenue (est.) $62.6b (FY, 2025) | Revenue (est.) $94.2b (FY, 2025) | Revenue (est.) $61.2b (FY, 2025) | Revenue (est.) €21.1b (FY, 2025) | Revenue (est.) $58.7b (FY, 2025) | Revenue (est.) $65.2b (FY, 2025) |
Cost of goods | Cost of goods ¥415.8b (FY, 2024) | Cost of goods N/A | Cost of goods $6.2b (FY, 2025) | Cost of goods $1.3b (FY, 2025) | Cost of goods CHF2.1b (FY, 2025) | Cost of goods $3.4b (FY, 2024) | Cost of goods $16.1b (FY, 2025) | Cost of goods $30.3b (FY, 2025) | Cost of goods $18.2b (FY, 2025) | Cost of goods €6.5b (FY, 2025) | Cost of goods $4.9b (FY, 2025) | Cost of goods $11.1b (FY, 2025) |
Gross profit | Gross profit ¥1.5t (FY, 2024) | Gross profit N/A | Gross profit $23.2b (FY, 2025) | Gross profit $4.7b (FY, 2025) | Gross profit CHF4.5b (FY, 2025) | Gross profit $953m (FY, 2024) | Gross profit $46.5b (FY, 2025) | Gross profit $63.9b (FY, 2025) | Gross profit $43b (FY, 2025) | Gross profit €15b (FY, 2025) | Gross profit $54.2b (FY, 2025) | Gross profit $54.1b (FY, 2025) |
Net income | Net income ¥295.8b (FY, 2024) | Net income $4.5b (FY, 2025) | Net income $8.5b (FY, 2025) | Net income $1.1b (FY, 2025) | Net income CHF909m (FY, 2025) | Net income ($1b) (FY, 2024) | Net income $7.8b (FY, 2025) | Net income $26.8b (FY, 2025) | Net income $4.2b (FY, 2025) | Net income €2.6b (FY, 2025) | Net income $10.2b (FY, 2025) | Net income $20.6b (FY, 2025) |
Operating ⚠ | ||||||||||||
Countries | Countries N/A | Countries N/A | Countries 35 (FY, 2021) | Countries 100 (FY, 2022) | Countries 28 (FY, 2022) | Countries 80 (FY, 2023) | Countries 200 (FY, 2024) | Countries N/A | Countries 70 (FY, 2022) | Countries 66 (FY, 2021) | Countries 130 (FY, 2021) | Countries 120 (FY, 2021) |
Manufacturing Facilities | Manufacturing Facilities 13 (Jun, 2022) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 7 (FY, 2022) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 19 (FY, 2022) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A |
Manufacturing Facilities (United States) | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) 28 (FY, 2022) | Manufacturing Facilities (United States) 11 (FY, 2022) | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A |
Phase I Trials Products | Phase I Trials Products 16 (FY, 2018) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 51 (FY, 2024) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 27 (FY, 2019) |
Phase II Trials Products | Phase II Trials Products 7 (FY, 2018) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 27 (FY, 2024) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 8 (FY, 2021) |
Phase III Trials Products | Phase III Trials Products 7 (FY, 2018) | Phase III Trials Products N/A | Phase III Trials Products 9 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 32 (FY, 2024) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 10 (FY, 2021) |
Products | Products N/A | Products 11 (FY, 2022) | Products 21 (FY, 2021) | Products N/A | Products N/A | Products 8 k (FY, 2023) | Products N/A | Products N/A | Products N/A | Products 300 k (FY, 2021) | Products N/A | Products N/A |
Trademarks | Trademarks 112 (Jun, 2022) | Trademarks 20 (FY, 2022) | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A |
Funding | ||||||||||||
Total funding raised | Total funding raised N/A | Total funding raised $ 53.9m | Total funding raised N/A | Total funding raised $ 307.2m | Total funding raised N/A | Total funding raised $ 650m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 3.8b | Total funding raised $ 121m | Total funding raised $ 1b | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Regeneron Pharmaceuticals
HQ
Tarrytown, US
Employees
15,106↑ 8% increase
Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.
View companyGilead Sciences
HQ
Foster City, US
Employees
18,000↑ 6% increase
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.
View companyEdwards Lifesciences
HQ
Irvine, US
Employees
15,800↓ 20% decrease
Edwards Lifesciences is a provider of patient-focused medical solutions for structural heart disease and critical care monitoring.
View company
Lonza
HQ
Basel, CH
Employees
19,771↑ 2% increase
Lonza Group is a company specializing in life sciences and biotechnology solutions
View company